Elvinix Inc. has announced an exclusive license agreement with Zealand Pharma A/S granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio.
Elvinix Inc. has announced an exclusive license agreement with Zealand Pharma A/S granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio.